Efficacy of gefitinib-celecoxib combination therapy in docetaxel-resistant prostate cancer
Lin JZ, Hameed I, Xu Z, Yu Y, Ren ZY, Zhu JG. Efficacy of gefitinib-celecoxib combination therapy in docetaxel-resistant prostate cancer. Oncology Reports 2018, 40: 2242-2250. PMID: 30066906, DOI: 10.3892/or.2018.6595.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBiomarkers, TumorCelecoxibCell ProliferationCyclooxygenase 2 InhibitorsDocetaxelDrug Resistance, NeoplasmGefitinibHumansMaleMiceMice, Inbred BALB CMice, NudeNeoplasm InvasivenessProstatic NeoplasmsQuinazolinesTaxoidsTumor Cells, CulturedXenograft Model Antitumor AssaysConceptsCastration-resistant prostate cancerDocetaxel-resistant castration-resistant prostate cancerEpidermal growth factor receptorCombination therapyCOX-2Prostate cancerKi-67Human castration-resistant prostate cancerCOX-2 protein expression levelsDocetaxel-resistant prostate cancerCombined inhibitionCleaved-caspase-3 protein expressionDocetaxel-resistant prostate cancer cell linesCombination therapy groupDose-escalating mannerProstate cancer cell linesMajor clinical problemABCB1 expression levelsBcl-2COX-2 inhibitionEffect of gefitinibNovel combination therapiesFluorescence-activated cell sorting (FACS) analysisExpression levelsCell lines